- Details
- Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...
|
- Details
- Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...
|
- Details
- In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...
|
- Details
- Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...
|
- Details
- Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...
|
- Details
- Howard Scher presents an overview of treatment options for non-metastatic castration-resistant prostate cancer, (nmCRPC), those patients who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan and CT abdomen/pelvis +/- and MRI. These patients are generally asymptomatic from cancer itself with some symptoms from prior therapies. Importantly, t...
|
- Details
- Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...
|
- Details
- Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the quality of life data from the ARAMIS trial. The data suggest that adding darolutamide (systemic therapy) to ADT compared to ADT alone improves quality of life in the patients, and these include bowel and urinary symptom benefits along with the skeletal outcomes and quality-of-life measures. The ARAMIS study suggests that androgen receptor antagonist da...
|
- Details
- Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...
|
